Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2698  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (388 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed471    
    Printed3    
    Emailed0    
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
COMMENTARY
Year : 2019  |  Volume : 67  |  Issue : 6  |  Page : 1437-1438

Commentary on Brain Metastasis from Ovarian Carcinoma: Evaluation of Prognostic Factors and Treatment


Department of Neurosurgery, Tata Memorial Hospital, Mumbai, Maharashtra, India

Date of Web Publication20-Dec-2019

Correspondence Address:
Dr. Aliasgar Moiyadi
Department of Neurosurgery, Tata Memorial Hospital, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.273610

Rights and Permissions



How to cite this article:
Moiyadi A, Shaikh S. Commentary on Brain Metastasis from Ovarian Carcinoma: Evaluation of Prognostic Factors and Treatment. Neurol India 2019;67:1437-8

How to cite this URL:
Moiyadi A, Shaikh S. Commentary on Brain Metastasis from Ovarian Carcinoma: Evaluation of Prognostic Factors and Treatment. Neurol India [serial online] 2019 [cited 2020 Jul 12];67:1437-8. Available from: http://www.neurologyindia.com/text.asp?2019/67/6/1437/273610




Brain metastases from ovarian cancers are extremely rare, and the incidence is probably vastly underreported due to the absence of routine brain imaging even in disseminated ovarian cancers. Wohl et al. are to be commended for addressing this rare group of metastases.[1]

Ovarian cancers are generally advanced at the time of diagnosis (FIGO stage III and IV). Though the brain is not a common site of metastases, this advanced stage cohort is the subset that is most likely to have associated brain metastases. This is reflected in the present study, where almost half of the cases were disseminated, to begin with. Mentioning that the denominator of their sample would have added more value to this article since it would help establish an incidence metric for brain metastases from ovarian cancers. Although brain metastasis remains a rare occurrence in ovarian cancers, the incidence is higher than that seen in the rest of the female genital tract malignancies put together.[2] As with many other cancers, with improvements in the treatment of the primary disease (especially in the post-platinum based chemotherapy era for ovarian cancers) leading to prolongation of survival coupled with improving detection methods, the incidence of brain metastases is increasing. Whether this case is selected as the kind which eventually gets included in the brain metastases series, yet remains difficult to be determined.

Most brain metastases in ovarian cancers are metachronous with intervals from initial diagnosis ranging from 1–4 years. Interestingly in this study by Wohl et al., the disease-free interval was shorter (24 months vs 44 months, [Table 2] from Whol et al.) for the survivors compared to those that died. However, this is most likely the result indicating a small number of survivors.

Serum CA-125 level is a reliable tumor marker of ovarian cancer. However, in patients with brain metastasis, even though there are a few series that show raised values at the time of diagnosis, in the majority of the patients, it has not been proven to be a reliable marker of brain metastasis.[3] Wohl et al. did not report on this, and it may have been pertinent to describe their findings in this respect.

The RTOG recursive partitioning analysis index (RPA) and more recently, the graded prognostic assessment (GPA) index have been used in most brain metastases studies to analyze the various prognostic factors. Due to the rarity of brain metastases in ovarian cancers, this has not found much application in most series of ovarian cancers. Nevertheless, the present study shows that solitary brain metastases and combined modality treatment (surgery with radiation) favourably influence overall survival and progression-free survival, respectively. This again resonates with the overall understanding of brain metastases and the changing paradigms in treatment. Surprisingly, however, they did not find the presence of systemic disease to be a poor prognostic factor, and this could reflect the relative efficacy of systemic therapies in ovarian cancers with extracranial metastases.

A systematic review of 57 similar studies and 591 patients by Pakneshan et al. in 2014, confirmed that survival is related to the patient's age, performance status, and absence of multiple intracranial metastases. These findings are consistent with those reported in this series.[4] More systematic reporting of data from larger patient cohorts will clarify decision-making algorithms in the future.



 
  References Top

1.
Wohl A, Kimchi G, Korach J, Perri T, Zach L, Zibly Z, et al. Brain metastases from ovarian carcinoma: Evaluation of prognostic factors and treatment. Neurol India 2019;67:1431-6.  Back to cited text no. 1
  [Full text]  
2.
Ogawa K, Yoshii Y, Aoki Y, Nagai Y, Tsuchida Y, Toita T, et al. Treatment and prognosis of brain metastases from gynecological cancers. Neurol Med Chir (Tokyo) 2008;48:57-62.  Back to cited text no. 2
    
3.
Tay SK, Rajesh H. Brain metastases from epithelial ovarian cancer. Int J Gynecol Cancer 2005;15:824-82.  Back to cited text no. 3
    
4.
Pakneshan S, Safarpour D, Tavassoli F, Jabbari B. Brain metastasis from ovarian cancer: A systematic review. J Neurooncol 2014;119:1-6.  Back to cited text no. 4
    




 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow